價(jià)格 | 詢價(jià) | ||
包裝 | 100ug | 500ug | 1000ug |
最小起訂量 | 100ug |
發(fā)貨地 | 北京 |
更新日期 | 2025-07-18 |
中文名稱:MERTK酶 | 英文名稱:MERTK |
品牌: 百普賽斯 | 產(chǎn)地: 北京 |
保存條件: -20°C to -70°C | 純度規(guī)格: 99.9% |
產(chǎn)品類別: 重組蛋白 | |
貨號(hào): MERTK | 用途范圍: 藥物開發(fā)等 |
規(guī)格: 100ug | 是否進(jìn)口: 否 |
英文名稱:Tyrosine-protein kinase Mer
中文名稱:Mer受體酪氨酸激酶
靶點(diǎn)別稱:MERTK,Mer
物種:Human/Mouse/Cynomolgus
屬性:Protein
標(biāo)記:Unconjugated
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>90% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
Tyrosine-protein kinase Mer(MERTK) is a member of the TYRO3/AXL/MER (TAM) receptor kinase family and encodes a transmembrane protein with two fibronectin type-III domains, two Ig-like C2-type (immunoglobulin-like) domains, and one tyrosine kinase domain. Following activation by ligand, interacts with GRB2 or PLCG2 and induces phosphorylation of MAPK1, MAPK2, FAK/PTK2 or RAC1. MERTK signaling plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment. Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. Plays also an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1, which selectively induces production of suppressors of cytokine signaling SOCS1 and SOCS3.
成立日期 | 2010-07-22 (16年) | 注冊(cè)資本 | 8000萬(wàn)人民幣 |
員工人數(shù) | 500人以上 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營(yíng)行業(yè) | 醫(yī)藥中間體,原料藥,激素類,氨基糖苷類,中樞神經(jīng)系統(tǒng)用藥 | 經(jīng)營(yíng)模式 | 工廠,試劑 |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP1年
|
上海切爾齊生物科技有限公司
|
2025-05-25 | |
詢價(jià) |
碧云天生物技術(shù)有限公司
|
2025-08-02 | ||
¥960.00 |
VIP10年
|
北京索萊寶科技有限公司
|
2025-08-04 | |
¥1580 |
VIP3年
|
上海滬震實(shí)業(yè)有限公司
|
2025-08-04 |